Japan's Daiichi Sankyo Co said on Friday it will tie up with Britain's GlaxoSmithKline PLC to bring new vaccines to the Japanese market, known for its slow acceptance of vaccines.

Northern TK Venture filed a claim against Daiichi Sankyo saying the latter prevented NTK from proceeding with its open offer. IHH Healthcare is seeking compensation of up to $1.7b (₹109.3b) from ...

Japan's Daiichi Sankyo Company Ltd is selling its stake worth up to $3.6 billion in Indian drugmaker Sun Pharmaceutical Industries Ltd, a person directly involved in the deal said on Monday.

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be in the works from Korea’s Alteogen following a licensing deal worth ...

Daiichi Sankyo Co (OTCMKTS:DSNKY) just reported results for the first quarter of 2024. Daiichi Sankyo Co reported earnings per share of 27 cents. The company reported revenue of $2.80 billion.

Daiichi Sankyo gins up antibody research project with German research institute By Darren Incorvaia Jan 14, 2025 3:44pm Daiichi Sankyo multi-specific therapeutic antibodies solid tumor ...

Summary. Daiichi Sankyo is poised to play its part in revolutionizing cancer treatments with its portfolio of antibody-drug conjugates, that target $15 billion-plus annual revenue opportunities.

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

Enhertu logged sales of $3.75 billion in Daiichi’s 2024 fiscal year, which concluded at the end of March. The company is projecting sales of the treatment to reach 662 billion Japanese yen in ...

Summary. Daiichi Sankyo's stock has dropped 25% since my last update due to disappointing clinical data from Dato-DXd studies, but upcoming read-outs in 2025 could drive a meaningful rebound.